Partial salary support is requested for the Senior Leadership of the University of Virginia Cancer Center, consisting of the Director, Michael J. Weber, Ph.D., 50% salary; Geoffrey R. Weiss, M.D., Deputy Director for Clinical Research and Clinical Affairs, 30% salary; Sarah J. Parsons, Ph.D., Associate Director for Basic Research, 20% salary; Jay W. Fox, Ph.D., Associate Director for Shared Resources, 15% salary; and Peyton T. Taylor, M.D., Medical Director, 10% salary. In each case, the requested salary is less than the percent effort dedicated to the Cancer Center. Dr. Weber plays a leadership and oversight role in all aspects of the Cancer Center, chairing both the CCSG Executive Committee, which is the major organizational tool for fostering basic, translational, and clinical cancer research, and the Cancer Center Management Group, which integrates research and care. Dr. Weiss's role is to provide oversight of and leadership for all the clinical operations of the Cancer Center, including clinical research and care. Dr. Parsons serves as the primary liaison between the laboratory based research of the Cancer Center (Programs 1-6) and the clinical research centered in Program 7- Developmental Therapeutics. Dr. Fox offers leadership and guidance to the Shared Resource Directors and Faculty Directors for scientifically sophisticated and fiscally effective operation of the Cores for the expressed benefit of Cancer Center members. Dr. Taylor's role in the CCSG as Medical Director is to ensure that the oncology clinical enterprise functions to support clinical and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-18
Application #
7726767
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
18
Fiscal Year
2008
Total Cost
$138,899
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255

Showing the most recent 10 out of 539 publications